The prospect of using short interfering RNA reagents as therapeutics is still fairly theoretical, but that isn’t stopping entrepreneurs from setting up businesses around the idea. In fact, a round of consolidation earlier this summer coupled with new venture capital funding seems to indicate a healthy dose of investor confidence in the tiny sector.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.